✦ LIBER ✦

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication

✍ Scribed by Rajagopalan, S.; Mohler, E.R.; Lederman, R.J.

Book ID: 123285504
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 33 KB
Volume: 39
Category: Article
ISSN: 1097-6809
DOI: 10.1016/j.jvs.2003.12.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Regional angiogenesis with vascular endo

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase ii randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication

✍ S. Rajagopalan; E.R. Mohler; R.J. Lederman 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 32 KB

Plasma Levels of Soluble Tie2 and Vascul

Plasma Levels of Soluble Tie2 and Vascular Endothelial Growth Factor Distinguish Critical Limb Ischemia From Intermittent Claudication in Patients With Peripheral Arterial Disease

✍ Clarence M. Findley; Robert G. Mitchell; Brian D. Duscha; Brian H. Annex; Christ 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 207 KB

Plasma Levels of Soluble Tie2 and Vascul

Plasma Levels of Soluble Tie2 and Vascular Endothelial Growth Factor Distinguish Critical Limb Ischemia from Intermittent Claudication in Patients with Peripheral Arterial Disease

✍ C.M. Findley; R.G. Mitchell; B.D. Duscha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase II study of SU5416—a small-molecul

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

✍ Francis J. Giles; Maureen A. Cooper; Lewis Silverman; Judith E. Karp; Jeffrey E. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are of adverse prognostic significance in patients with myeloproliferative disorders (MPD), including agnogenic myeloid metaplasia (AMM), chronic myeloid leukemia in blastic phase (CML

Randomized, Placebo-Controlled, Phase II

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

✍ Hecht, J. R.; Trarbach, T.; Hainsworth, J. D.; Major, P.; Jager, E.; Wolff, R. A 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 175 KB